A study of DKD drug monlunabant failed to meet its primary endpoint, but not all the kidney disease news in Novo Nordisk's 2024 financial report was bleak. #NovoNordisk #kidneydisease #diabetickidneydisease #drugdevelopment #nephrology #nephsky
Comments
Log in with your Bluesky account to leave a comment
Comments